In vitro Effects of Aprosulate sodium, a Novel Anticoagulant, On Platelet Activation: Possible Mechanism for Antiplatelet Action

Summary

Aprosulate sodium, a bis-lactobionic acid amide derivative, is a novel synthetic polyanion with potent anticoagulant activities. In the present study, the effects of aprosulate on platelet aggregation were investigated in a plasma-free system. Aprosulate inhibited thrombin (0.03-0.3 U/ml)-induced aggregation in rat washed platelets in a concentration-dependent manner, with an IC₅₀ value of 0.38 Μg/ml. In contrast, aprosulate, at up to 10 Μg/ml, did not affect collagen (1 Μg/ml) - or ADP (3 ΜM)-induced aggregation. In fura 2-loaded platelets, aprosulate (1-10 Μg/ml) inhibited intracellular Ca²⁺ mobilization induced by thrombin, but not that by ADP. Protamine, a highly basic protein, abolished aprosulate-mediated inhibition of thrombin-induced platelet aggregation, suggesting that the observed inhibition is primarily due to the negative charge contained on the aprosulate molecule. In human platelets, aprosulate inhibited thrombin-induced aggregation, but failed to inhibit platelet aggregation induced by SFLLRN, a synthetic tethered ligand of a thrombin receptor. Antiplatelet profiles of aprosulate were largely similar to those of heparin, although heparin inhibited both thrombin- and collagen-induced aggregation. These in vitro studies indicate that aprosulate is capable of inhibiting thrombin-induced platelet activation and that this effect is independent of its anticoagulant activity. These results suggest that the polyanionic feature of aprosulate plays an essential role in promoting its antiplatelet activities, and that a plausible mechanism to explain the observed inhibition conferred by this agent, would be one which involves blocking the platelet-thrombin interaction.

• References

• 1 Klauser RJ, Raake W, Meinetsberger E, Zeiller P. Antithrombotic and anticoagulant properties of synthetic poly anions: sulfated bis-aldonic acid amides. J Pharmacol Exp Ther 1991; 259: 8-14
• 2 Sugidachi A, Asai F, Koike H. In vivo pharmacology of aprosulate, a new synthetic polyanion with anticoagulant activity. Thromb Res 1993; 69: 71-80
• 3 Klauser RJ, Meinetsberger E, Raake W. Biochemical studies of sulfated lactobionic acid amides. Semin Thromb Haemost 1991; 17 (Suppl. 01) 118-125
• 4 Rosenberg RD. Biochemistry of heparin antithrombin interactions, and the physiologic role of this natural anticoagulant mechanism. Am J Med 1989; 87: 2S-9S
• 5 Sugidachi A, Asai F, Koike H. Anticoagulant and antiprotease activities of aprosulate sodium, a new synthetic polyanion, in human plasma and purified systems. Blood Coagul Fibrinolysis 1994; 5: 773-779
• 6 Klauser RJ. Interaction of the sulfated lactobionic acid amide LW 10082 with thrombin and its endogenous inhibitors. Thromb Res 1991; 62: 557-565
• 7 Ofosu FA, Fareed J, Smith LM, Anvari N, Hoppensteadt D, Blajchman MA. Inhibition of factor X, factor V and prothrombin activation by the bis (lactobionic acid amide) LW 10082. Eur J Biochem 1992; 203: 121-125
• 8 Eika C. On the mechanism of platelet aggregation induced by heparin, protamine and polybrene. Scand J Haematol 1972; 9: 248-257
• 9 Ellison N, Edmunds Jr LH, Colman RW. Platelet aggregation following heparin and protamine administration. Anesthesiology 1978; 48: 65-68
• 10 Celia G, Scattolo N, Luzzatto G, Stevanato F, Vio C, Girolami A. Effects on platelets and on the clotting system of four glycosaminoglycans extracted from hog mucosa and one extracted from aortic intima of the calf. J Med 1986; 17: 331-346
• 11 Messmore Jr HL, Griffin B, Fareed J, Coyne E, Seghatchian J. In vitro studies of the interaction of heparin, low molecular weight heparin and heparinoids with platelets. Ann NY Acad Sci 1989; 556: 217-232
• 12 Luzzatto G, Paolini R, Stevanato F, Simioni P, Celia G. Effects of glycosaminoglycans and protamine chloridrate on platelet aggregation induced by collagen and thrombin. Angiology 1989; 40: 170-174
• 13 Cofrancesco E, Colombi M, Gianese F, Cortellaro M. The effect of dermatan sulfate on in vitro human plasma coagulation, platelet aggregation and beta TG/PF4 release. Thromb Res 1990; 57: 405-414
• 14 Raake W, Klauser RJ, Elling H, Meinetsberger E. Anticoagulant and antithrombotic properties of synthetic sulfated bis-lactobionic acid amides. Thromb Res 1989; 56: 719-730
• 15 Sugidachi A, Asai F, Oshima T, Koike H. Age-associated changes in intracellular Ca²⁺ mobilization and basal pH level in rat platelets. Platelets 1993; 4: 91-95
• 16 Grynkiewicz G, Poenie M, Tsien Y. A new generation of Ca²⁺ indicators with greatly improved fluorescence properties. J Biol Chem 1985; 260: 3440-3450
• 17 Connolly TM, Condra C, Feng DM, Cook JJ, Stranieri MT, Reilly CF, Nutt RF, Gould RJ. Species variability in platelet and other cellular responsiveness to thrombin receptor-derived peptides. Thromb Haemost 1994; 72: 627-633
• 18 Asai F, Sugidachi A, Koike H. Anticoagulant and antithrombotic activities of aprosulate (LW 10082), unfractionated and low molecular weight heparins. Ann Hematol 1992; 64: A64
• 19 Raake W, Klauser R. Antithrombotic activities of aprosulate sodium (LW 10082) - a synthetic bis-lactobionic acid amide. Arch Pharmacol 1991; 344 (Suppl. 01) R55
• 20 Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991; 64: 1057-1068
• 21 Coughlin SR. Thrombin receptor structure and function. Thromb Haemost 1993; 70: 184-187
• 22 Harmon JT, Jamieson GA. Platelet activation by thrombin in the absence of the high-affinity thrombin receptor. Biochemistry 1988; 27: 2151-2157
• 23 Greco NJ, Jamieson GA. High and moderate affinity pathways for a-throm-bin-induced platelet activation. Proc Soc Exp Biol Med 1991; 198: 792-799
• 24 Seiler SM, Peluso M, Michel IM, Goldenberg H, Fenton JWII, Riexinger D, Natarajan S. Inhibition of thrombin and SFLLR-peptide stimulation of platelet aggregation, phospholipase A₂ and Na⁺/H⁺ exchange by a thrombin receptor antagonist. Biochem Pharmacol 1995; 49: 519-528
• 25 Cumming AM, Jones GR, Wensley RT, Cundall RB. In vitro neutralization of heparin in plasma prior to the activated partial thromboplastin time test: an assessment of four heparin antagonists and two anion exchange resins. Thromb Res 1986; 41: 43-56
• 26 Vu TK, Wheaton VI, Hung DT, Charo I, Coughlin SR. Domains specifying thrombin-receptor interaction. Nature 1991; 353: 674-677
• 27 Church FC, Pratt CW, Noyes CM, Kalayanamit T, Sherrill GB, Tobin RB, Meade JB. Structural and functional properties of human a-thrombin, phosphopyridoxylated α-thrombin, and γ_T-thrombin. J Biol Chem 1989; 264: 18419-18425
• 28 Karshikov A, Bode W, Tulinsky A, Stone SR. Electrostatic interactions in the association of proteins: an analysis of the thrombin-hirudin complex. Protein Sci 1992; 1: 727-735
• 29 Sobel M, Adelman B. Characterization of platelet binding of heparins and other glycosaminoglycans. Thromb Res 1988; 50: 815-826
• 30 Rajtar G, Marchi E, de Gaetano G, Cerletti C. Effects of glycosaminoglycans on platelet and leukocyte function: role of N-sulfation. Biochem Pharmacol 1993; 46: 958-960
• 31 Home III MK, Chao ES. Heparin binding to resting and activated platelets. Blood 1989; 74: 238-243
• 32 Carter CJ, Kelton JG, Hirsh J, Cerskus A, Santos AV, Gent M. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood 1982; 59: 1239-1245
• 33 Cade JF, Buchanan MR, Boneu B, Ockelford P, Carter CJ, Cerskus AL, Hirsh J. A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: the influence of the method of preparation. Thromb Res 1984; 35: 613-625